Beone Medicines is a global oncology company discovering and developing treatments for cancer, with a primary focus on hematology and solid tumors. The company's core franchise in chronic lymphocytic leukemia (CLL) includes the Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA (zanubrutinib), the B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax, and the BTK chimeric degradation activation compound (BTK-CDAC) BGB-16673. Its solid tumor portfolio features the anti-PD-1 antibody TEVIMBRA (tislelizumab) and investigational assets including the CDK4 inhibitor BGB-43395, the B7-H4 antibody-drug conjugate BG-C9074, the GPC3-dependent 4-1BB bispecific T-cell engager BGB-B2033, the PRMT5 inhibitor BGB-58067, and the CEA ADC BG-C477. Beone Medicines operates an integrated model with in-house clinical development and manufacturing capabilities across the U.S., China, the UK, and Australia. The company serves markets in the U.S., Europe, Japan, Korea, and Brazil, and has established partnerships with Amgen, Novartis, and Celgene. Founded in 2010 by John V. Oyler and Xiaodong Wang, the company was formerly known as BeiGene.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage beonemedicines.com
Sector Healthcare IR page ir.beonemedicines.com
Tags
oncology, hematology, solid tumors, btk inhibitors, bcl2 inhibitors, antibody-drug conjugates, bispecific antibodies, protein degraders, cll, mantle cell lymphoma, lung cancer, breast cancer, BRUKINSA, zanubrutinib, sonrotoclax, BGB-16673, TEVIMBRA, tislelizumab, BGB-43395, BG-C9074, BGB-B2033, BGB-58067, BG-C477, lifirafenib, pamiparib, BGB-3111, BeOne Care Foundation
Press page beonemedicines.com/newsroom

Metrics

Valuation  
Market cap $ 602.148B
Market cap (USD) $ 602.148B
P/E 665.49
PEG —
P/BV 103.45
P/S 91.14
P/OCF 378.66
P/FCF 415.49
Dividend yield —
Turnover / mcap —
Returns  
ROE 7.5%
ROI 5.3%
ROIC 5.7%
Profit margin 5.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 18.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score 5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 5.343B 3.81B 2.459B 1.416B 1.176B 308.874M 428.212M 198.22M 238.387M
Net profit 286.933M -644.786M -881.708M -2.004B -1.413B -1.601B -950.578M -674.033M -93.299M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 2.99 1.74 20.63 2.2 32.03 2.19 20.58 10.6 —
Price performance 12m 0.72 -0.92 8.35 -0.93 13.69 -0.89 0.94 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Beone Medicines Ltd. (ticker 6160), listed in United States.

Company History

Date Change Detail
May 27, 2025 Renamed BEIGENE, LTD. → BEONE MEDICINES LTD.
— Former tickers BGNE

ETFs Holding Beone Medicines Ltd.

ETF Weight in ETF Shares Market value As of
CANC 3.18% 18,669 $ 6.713M Aug 31, 2026
SAGP 1.63% 57,500 $ 1.249M Jun 30, 2026
PCCE 1.12% 800 $ 17.382K Jun 30, 2026
CGGO 0.85% 240,864 $ 99.065M Nov 16, 2026
CGGE 0.82% 64,959 $ 26.717M Nov 16, 2026
CGIE 0.70% 41,231 $ 16.958M Nov 16, 2026
CGNG 0.68% 48,251 $ 19.845M Nov 16, 2026
FEMR 0.64% 37,464 $ 1.011M Jun 30, 2026
EMEQ 0.61% 14,328 $ 4.083M Jun 30, 2026
TMED 0.40% 322 $ 91.76K Jun 30, 2026
FFEM 0.36% 711 $ 224.683K Jul 31, 2026
HELX 0.23% 225 $ 64.118K Jun 30, 2026
APIE 0.19% 6,192 $ 2.227M Aug 31, 2026
DFAE 0.18% 311,330 $ 16.182M Nov 12, 2026
DFSE 0.15% 8,670 $ 884.576K Nov 12, 2026
AVSE 0.15% 7,703 $ 318.867K Nov 16, 2026
TIER 0.15% 2,100 $ 51.912K Jul 31, 2026
NTSE 0.14% 273 $ 77.797K Jun 30, 2026
REMG 0.13% 6,600 $ 143.397K Jun 30, 2026
AVEM 0.11% 744,667 $ 27.651M Nov 16, 2026
FTLS 0.10% 6,527 $ 0.00 Nov 16, 2026
DFEM 0.10% 61,403 $ 8.52M Nov 12, 2026
DEHP 0.09% 2,501 $ 350.283K Nov 12, 2026
JSTC 0.08% 586 $ 241.016K Nov 17, 2026
DFAX 0.02% 44,007 $ 2.434M Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
ONC canonical Common share — US nasdaq 405.95 USD 2026-11-06
6160 Common share — HK hkex 242.60 HKD 2026-11-19
BEIGF Common share — US otc — —